BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21039548)

  • 1. Solubilisation of drugs within liposomal bilayers: alternatives to cholesterol as a membrane stabilising agent.
    Ali MH; Kirby DJ; Mohammed AR; Perrie Y
    J Pharm Pharmacol; 2010 Nov; 62(11):1646-55. PubMed ID: 21039548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal drugs dispersed in hydrogels. Effect of liposome, drug and gel properties on drug release kinetics.
    Mourtas S; Fotopoulou S; Duraj S; Sfika V; Tsakiroglou C; Antimisiaris SG
    Colloids Surf B Biointerfaces; 2007 Apr; 55(2):212-21. PubMed ID: 17223020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol.
    Devaraj GN; Parakh SR; Devraj R; Apte SS; Rao BR; Rambhau D
    J Colloid Interface Sci; 2002 Jul; 251(2):360-5. PubMed ID: 16290741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of lipid geometry in designing liposomes for the solubilisation of poorly water soluble drugs.
    Ali MH; Moghaddam B; Kirby DJ; Mohammed AR; Perrie Y
    Int J Pharm; 2013 Aug; 453(1):225-32. PubMed ID: 22766442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.
    Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
    Int J Pharm; 2006 Apr; 312(1-2):53-60. PubMed ID: 16469460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome formulation of poorly water soluble drugs: optimisation of drug loading and ESEM analysis of stability.
    Mohammed AR; Weston N; Coombes AG; Fitzgerald M; Perrie Y
    Int J Pharm; 2004 Nov; 285(1-2):23-34. PubMed ID: 15488676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microfluidic-controlled manufacture of liposomes for the solubilisation of a poorly water soluble drug.
    Kastner E; Verma V; Lowry D; Perrie Y
    Int J Pharm; 2015 May; 485(1-2):122-30. PubMed ID: 25725309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation.
    El-Samaligy MS; Afifi NN; Mahmoud EA
    Int J Pharm; 2006 Feb; 308(1-2):140-8. PubMed ID: 16356669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclodextrins in drug delivery.
    Loftsson T; Jarho P; Másson M; Järvinen T
    Expert Opin Drug Deliv; 2005 Mar; 2(2):335-51. PubMed ID: 16296758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and physico-chemical characterization of a liposomal formulation of istaroxime.
    Luciani P; Fevre M; Leroux JC
    Eur J Pharm Biopharm; 2011 Oct; 79(2):285-93. PubMed ID: 21550400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal drug delivery systems: from concept to clinical applications.
    Allen TM; Cullis PR
    Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardanol as a replacement for cholesterol into the lipid bilayer of POPC liposomes.
    De Maria P; Filippone P; Fontana A; Gasbarri C; Siani G; Velluto D
    Colloids Surf B Biointerfaces; 2005 Jan; 40(1):11-8. PubMed ID: 15620834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery.
    Fahr A; van Hoogevest P; May S; Bergstrand N; S Leigh ML
    Eur J Pharm Sci; 2005 Nov; 26(3-4):251-65. PubMed ID: 16112849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceutical applications of cyclodextrins: basic science and product development.
    Loftsson T; Brewster ME
    J Pharm Pharmacol; 2010 Nov; 62(11):1607-21. PubMed ID: 21039545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
    Stevens PJ; Lee RJ
    Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
    Joguparthi V; Anderson BD
    J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method.
    Qiu L; Jing N; Jin Y
    Int J Pharm; 2008 Sep; 361(1-2):56-63. PubMed ID: 18573626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of intravesicular pH drift and membrane binding on the liposomal release of a model amine-containing permeant.
    Tejwani RW; Anderson BD
    J Pharm Sci; 2008 Jan; 97(1):381-99. PubMed ID: 17694543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coming of age of lipid-based drug delivery systems.
    Davis SS
    Adv Drug Deliv Rev; 2004 May; 56(9):1241-2. PubMed ID: 15109766
    [No Abstract]   [Full Text] [Related]  

  • 20. Microfluidics based manufacture of liposomes simultaneously entrapping hydrophilic and lipophilic drugs.
    Joshi S; Hussain MT; Roces CB; Anderluzzi G; Kastner E; Salmaso S; Kirby DJ; Perrie Y
    Int J Pharm; 2016 Nov; 514(1):160-168. PubMed ID: 27863660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.